Co-Diagnostics earns Buy rating, $5 price target from Maxim after releasing coronavirus test

Analysts at Maxim more than doubled the company's price after sales of its coronavirus test began in China

Sprouts growing from stacks of quarters leading to a jar of quarters
Maxim tagged the company with a Buy rating and increased its price target to $5

Co-Diagnostics Inc (NASDAQ:CODX) has caught the eye of analysts at Maxim Group as it moves ahead with its coronavirus diagnostic test. 

Maxim tagged the company with a Buy rating and increased its price target to $5 from $2, citing the speed at which Co-Diagnostics developed a detection test for the virus and its subsequent first sales in China.

“[The speed of development] highlights not just the platform's versatility, but also CDI's ability to produce tests in a time efficient manner as future threats emerge,” Maxim wrote. “We saw this with the Zika test and other viral tests from CDI.”

READ: Co-Diagnostics makes coronavirus diagnostic test available to researchers

The firm also noted Co-Diagnostics’ viral testing manufacturing facilities in India through its joint venture with CoSara Diagnostics.

Additionally, the Utah-based company recently boosted its balance sheet, raising roughly $15 million in two equity financings in January. The move “extended the company’s cash runway well into 2021, positioning it to unlock value in its commercial-stage infectious diseases testing platform.”

“We factor in dilution, roll our metrics forward to 2020, and lower the risk adjustment in our commercial model to 30%, from 75%,” Maxim wrote. “The net result raises our 12-month price target to $5 from $2.”

The coronavirus has killed at least 1,873 people and infected more than 72,000, according to CNN.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Co-Diagnostics

Price: 9.15 USD

Market: NASDAQ
Market Cap: $227.98 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Co-Diagnostics named herein, including the promotion by the Company of Co-Diagnostics in any Content on the Site, the Company receives from...



Full interview: Co-Diagnostics expects to win a CE mark-validated...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the Utah-based company expects to achieve a CE mark validation on its coronavirus detection test from the European Union by as early as next week. Egan says the company is very enthused by the entire process of the development...

on 02/21/2020

2 min read